Prognostic Value of CD133 and SOX2 in Advanced Cancer

Figure 7

Trial sequential analysis (TSA) for cancer-specific survival (CSS) and overall survival (OS) of CD133 positive expression (α = 5%, β = 20%, and the relative risk reduction (RRR) = 15%).